focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Airlines Soar, Oil Producers Slip After Iran Deal

Mon, 25th Nov 2013 11:52

LONDON (Alliance News) - The following stocks are the leading risers and fallers on the main London indices midday Monday.

-------

A deal reached in Geneva over the weekend concerning Iran's nuclear capabilities will see the county allow some facility inspections and give up some previously enriched uranium, as well as freezing construction on a plutonium reactor. In return, Iran will be have USD7 billion to USD10 billion of sanctions lifted, providing a huge boost to its crippled economy, as well as a boost to potential trading partners. The price of oil has dropped sharply since the deal was announced on Sunday, helping to lift airline stocks, and hitting oil producers. A barrel of Brent currently trades at USD109.11.

-------

FTSE 100 - WINNERS

International Consolidated Airlines, up 2.8%, and easyJet, up 1.7%, are two of the biggest gainers on the blue-chip index. As heavy fuel consumers, the companies are being lifted by the fall in oil prices as the Iran deal helps to stabilise international relations. Alongside this, Jefferies has raised IAG's price target to 410.00 pence from 355.00p, reiterating a Buy recommendation. The investment bank has increased easyJet to Buy from Hold, with a price target of 1,620.00p, as it believes that the company's recent strong performance can be sustained.

Petrofac climbs 1.6%. The company said its 50/50 joint venture with Korean Daelim Industrial Co. Ltd. has been awarded an Oman refinery improvement contract worth USD2.1 billion. Petrofac said that when complete, it is anticipated that the revamped facility will increase current output by more than 70%.

Diageo is up 1.2%. Competition regulator the Office of Fair Trading said its mulling an offer from the spirits and alcoholic drinks giant to sell most of its Whyte & Mackay business, in response to competition and pricing concerns for bottled blended Scotch whiskey after Diageo recently took a controlling stake in United Spirits Ltd.

-------

FTSE 100 - LOSERS

Babcock International Group is down 2.5% after the company confirmed that it is in exclusive discussions regarding the establishment of a joint venture with Avincis, a provider of aviation services for mission-critical operations. The fact that the shares are among the biggest blue-chip fallers suggests that there is a market feeling that Babcock may end up overpaying for Avincis or take on liabilities it shouldn't, says WH Ireland analyst Nick Spoliar. However, on the face of it, the potential partnership looks "very complementary," Spoliar added.

Tullow Oil, down 1.1%, BG Group, down 0.7%, BP, down 0.5%, and Royal Dutch Shell, off 0.3%, are all big fallers in the FTSE 100. The oil producers are falling on the back of the falling oil price.

-------

FTSE 250 - WINNERS

Chemring jumps 12% despite reporting a decline in revenues for the fourth quarter and fiscal 2013 as well as a decline in order book. The company said the board's expectations for fiscal 2013 trading performance remains in line with the previously given guidance. Further, Chemring has concluded that a number of business units do not form part of its longer term strategy, and that it has started a process to divest certain of these businesses which is expected to result in an improved financial position. Despite the adverse market backdrop, Chemring said it is making good progress with its strategic planning process, the majority of which is now complete. This provides a clearer view for each of its business units of their market environment, competitive dynamics and future prospects.

Cranswick is up 4.6%. The UK pork products supplier reported a 16% increase in its pretax profit of GBP26.1 million for the six months ended September 30, up from GBP22.4 million a year earlier. Rising input costs due to pig prices reaching record highs during the period was partially offset by on-going efficiency improvements, sales volume growth, and recent acquisitions. Revenues of GBP483.5 million in the first half were up 15% from GBP418.6 million a year earlier, driven by a combination of new products, new customers, and strong fresh pork and bacon sales. Cranswick increased its interim dividend by 6.4% to 10.0 pence per share, and said that it expects its full-year performance to be in line with expectations.

Oxford Instruments, up 3.6%. UBS has raised the company's price target to 1,600.00p from 1,560.00p, saying that it has turned a corner. "Although the interim results missed our forecasts, we had underestimated the first quarter's weakness and as such, the second quarter's momentum was actually better than expected," said Robbie Capp, an analyst at UBS. Capp is also confident that the indicative bid for Andor Technology is a good use of the company's balance sheet.

Thomas Cook Group climbs 2.7%. The travel operator is benefiting from the falling price of oil. Alongside this, the company has revealed that it is selling its specialist activity-tour operator Neilson Active Holidays Ltd to private equity firm Risk Capital Partners for GBP9.2 million. Thomas Cook said the sale is expected to be complete around December 10. Additionally, Numis has raised the company to Add from Hold, increasing its price target to 175.00 pence from 150.00p, following a period of consolidation on the back of the company's stellar rise through the first eight months of 2013. Further, investor interest may be wetted by preliminary results due Thursday and billed as "2013 Results and Strategy Update" the investment bank says.

JD Wetherspoon is up 2.2%. The company has exchanged contracts to buy its first bar in Ireland, the Irish Independent reported Monday, quoting the pub chain's founder and Chairman Tim Martin. The paper quotes Martin saying that the EUR3 million investment in a bar in Blackrock is part of a plan to invest up to EUR50 million in Ireland over the next five- to ten-years, with the pub chain targeting between 10 and 20 pubs over that period.

-------

FTSE 250 - LOSERS

Essar Energy falls 6.1% after its pretax loss widened in its first half as increased sales could not offset depreciation in the Indian rupee and increased costs. The company said its pretax loss widened to USD498.8 million for the six months ended September 30 from USD282.8 million the previous year. The majority of the company's losses came from a large increase in its foreign exchange losses, to USD482.7 million from USD134.0 million, due to the depreciation of the rupee, the majority of which are unrealised paper losses. Essar also was hit by a 2.9% increase in its cost of sales to USD12.81 billion from USD12.45 billion and an increase in selling and distribution charges to USD100.4 million from USD61.6 million the previous year. Essar is another company being hit by the falling price of oil.

-------

AIM - WINNERS

Armadale Capital jumps 18% after it said it got positive assay results from the Mpokoto Gold project in the Katanga Province in the Democratic Republic of Congo. The company said the results were returned from the final 20 holes of a drilling programme undertaken in 2011 by the previous operators at Mpokoto and not previously released. The company said 18 out of the 20 holes confirmed near surface mineralisation with strong potential to prove up future resource estimates. The project is anticipated to be a relatively low-cost heap leach operation with operating costs estimated at USD700-900 an ounce.

Top Level Domain Holdings is up 12% after it signed contracts for five new top-level domains, while its German unit has signed a contract for a German state domain. Top Level Domains said it has signed contracts for .horse, .cooking, .casa, .fishing, and .budapest. Its subsidiary Minds + Machines GmbH has signed a contract for .nrw, which will serve Germany's largest state, North-Rhine Westphalia.

Summit Corporation is up 11%. Summit has entered a strategic alliance with the University of Oxford that will strengthen its utrophin modulator programme for the treatment of the fatal muscle wasting disease, Duchenne Muscular Dystrophy. Under the deal, Summit will acquire exclusive commercial rights to a pipeline of novel, early-stage utrophin modulators and core biological screening technology, and an exclusive option to intellectual property that is related to the utrophin field generated during the alliance. Summit will also sponsor a drug discovery programme in the University research laboratories to identify and develop additional utrophin modulator drugs.

Reach4entertainment Enterprises climbs 11% after it said that it was confident in meeting market expectations for its full year, aftre performance across all of its operations improved its the second half. The company said its operations were trading profitably, and the focus on integrating its two events marketing businesses, Dewynters in London and SpotCo in New York, had continued to reap rewards.

-------

AIM - LOSERS

GEONG International is off 28% after it reported a lower order book, reiterated that it expects to report a loss for the six months to end-September and revenues of about GBP4.1 million, and said it expects its 2014 results to be in line with those it reported this year. The software company said its order book stood at GBP10 million at September 30, down from GBP11.5 million a year earlier.

Nature Group slides 22% after it warned that it expects its full-year results to be below market expectations after its maritime unit was hit by delays to the rebuild of a plant in Gibralter and higher costs in Rotterdam. The company said planning approval for rebuilding the Gibraltar plant, damaged by fire in May 2011, has been delayed due to the local planning authority requiring a limited Environmental Impact Assessment report over and above the work already carried out. On top of that, the company said it's experiencing difficult market conditions combined with higher costs at its Rotterdam operations after it had to comply with new legislation introduced in the Netherlands.

Hardide is down 17%. The company swung to a loss in its last financial year as it booked provisions for onerous lease and a writedown of assets, and revenues declined. Hardide reported a pretax loss of GBP900,000 for the 12 months to end-September compared with a profit of GBP300,000 a year earlier, as it booked a GBP400,000 provision for onerous lease and a GBP120,000 million impairment for its hibernated Houston facility. The surface coating technology said revenues fell to GBP2.4 million, from GBP2.9 million.

Surface Transforms drops 10% after it revealed that it has raised GBP327,000 through a placing of new shares, at a discounted price of 8.5 pence per share.

-------

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
27 Mar 2019 15:56

Summit Therapeutics Swings To Annual Profit On Sarepta Agreement

LONDON (Alliance News) - Summit Therapeutics PLC on Wednesday said it swung to a profit in its most recent financial year due to the recognition of revenue from its Sarepta Therapeutics Inc pretax

Read more
2 Jan 2019 14:08

Polar Capital Holds 6% Summit Therapeutics Stake After Deal (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Wednesday that Polar Capital LLP holds a 6.47% stake in the drug developer after a transaction on December 21.Polar Capital's the

Read more
17 Dec 2018 09:14

Summit Therapeutics proposes $25m fundraiser

(Sharecast News) - Antibiotics developer Summit Therapeutics has entered into a securities purchase agreement for the sale of $25m worth of its US-listed shares in order to extend its cash runway through to January 2020.

Read more
11 Dec 2018 16:34

Summit Therapeutics' loss expands on one-off charges

(Sharecast News) - Summit Therapeutics on Tuesday reported that its third quarter loss expanded due to one-off charges, but stated that the company has swung to a profit over the first nine months of the year.

Read more
11 Dec 2018 14:31

Summit Therapeutics Third-Quarter Loss Widens Due To One-Off Charges

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday its third-quarter loss widened sharply due to one-off charges.For the three months ended October 31, the company reported loss

Read more
6 Sep 2018 13:55

Summit Therapeutics Discovers New Antibiotics For Superbug Infections

LONDON (Alliance News) - Clinical stage drug company Summit Therapeutics PLC on Thursday said it has discovered multiple new mechanism antibiotics to treat "superbug" antibiotics are at

Read more
16 Aug 2018 13:53

Summit Therapeutics Shares Jump As Secures Extra USD12 Million Funding

LONDON (Alliance News) - Summit Therapeutics PLC on Thursday said it secured additional USD12 million from Biomedical Advanced Research & Development Authority, a division of the US Department

Read more
20 Apr 2018 13:11

Summit Therapeutics Gets Encouraging Results From Ezutromid Trials

LONDON (Alliance News) - Summit Therapeutics PLC on Friday said new work showed a correlation between a reduction in a muscle damage biomarker and the use of its proposed treatment said analysis a

Read more
19 Apr 2018 15:07

Summit Therapeutics Completes Dosing For PhaseOut Clinical Trial

LONDON (Alliance News) - Summit Therapeutics PLC said on Thursday it has completed the ezutromid dosing of patients with Duchenne muscular dystrophy for the full 48-week PhaseOut DMD clinical was

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
27 Mar 2018 12:18

Summit Therapeutics To Raise GBP15 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday that it intends to raise gross proceeds of up to GBP15.0 million via share placing.The to a

Read more
14 Mar 2018 17:52

Summit Therapeutics Reports Progress On PhaseOut DMD Trial

LONDON (Alliance News) - Summit Therapeutics PLC at the clinical conference in Arlington highlighted the rigour in the data collection in analysis for its PhaseOut Duchenne 2

Read more
1 Feb 2017 16:50

Summit Therapeutics outlines next stage of ridinilazole development

(ShareCast News) - Drug discovery and development company Summit Therapeutics outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration and European Medicines Agency. The AIM-traded firm said, with input from

Read more
1 Feb 2017 12:15

Summit Therapeutics Details Phase III Programme For Ridinilazole

Read more
18 Jan 2017 12:09

Summit Therapeutics Appoints David Roblin As Chief Operating Officer

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.